Related Experiment Video
Updated: Aug 8, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Interferon-beta counteracts inflammatory mediator-induced effects on brain endothelial cell tight junction
Poonam A Kuruganti1, Julian R Hinojoza, Mary Jane Eaton
1Department of Pathology, Stanford University School of Medicine, California 94305, USA.
Insights
Interferon-beta (IFN-beta) may protect the brain
Area of Science:
- Neuroimmunology
- Cell Biology
- Endothelial Cell Biology
Background:
- Endothelial cell (EC) dysfunction is implicated in central nervous system (CNS) inflammation in multiple sclerosis (MS).
- Interferon-beta (IFN-beta) is a therapeutic agent in MS, but its precise mechanisms of action on CNS ECs are not fully understood.
- Tight junction proteins like zonula occludens-1 (ZO-1) and -2 (ZO-2) are critical for maintaining EC barrier integrity.
Purpose of the Study:
- To investigate the effects of inflammatory mediators on EC tight junction molecules in human brain ECs.
- To determine the impact of IFN-beta on these inflammatory effects.
- To correlate in vitro findings with EC alterations observed in active MS lesions.
Main Methods:
- Cultured human brain ECs were treated with hydrogen peroxide (H2O2), tumor necrosis factor-beta, and interferon-gamma (IFN-gamma).
- Intracellular localization of ZO-1 and ZO-2 was analyzed using microscopy.
- Effects of co-treatments and IFN-beta were assessed.
- EC tight junction protein localization was examined in control white matter and active MS lesions.
Main Results:
- H2O2 induced reversible translocation of ZO-1 and ZO-2 from cell borders to the cytoplasm and EC retraction, without cytotoxicity.
- Tumor necrosis factor-beta mimicked H2O2 effects, while IFN-gamma did not.
- IFN-beta reversed the H2O2-induced alterations in ZO-1 and ZO-2 localization.
- In vitro findings mirrored EC ZO-1 distribution observed in active MS lesions.
Conclusions:
- Inflammatory mediators disrupt EC tight junction integrity, mimicking changes seen in active MS.
- IFN-beta treatment may counteract these inflammatory effects on CNS ECs.
- IFN-beta treatment has the potential to preserve EC barrier function in MS patients.
Abstract:
To elucidate mechanisms of endothelial cell (EC) dysfunction in CNS inflammatory responses and beneficial effects of interferon-beta (IFN-gamma) in multiple sclerosis (MS), we analyzed effects of individual and combinations of soluble inflammatory mediators on the intracellular localization of the EC tight junction-associated molecules zonula occludens-1 and -2 (ZO-1 and ZO-2) in human brain ECs. The cytoplasm in the majority of cells in control EC cultures was clear; ZO-1 and ZO-2 were localized peripherally near sites of cell contact and associated with submembranous cytoplasmic filaments. H2O2 induced reversible time- and concentration-dependent translocation of ZO-1 and ZO-2 to a random distribution within EC cytoplasm and retraction of EC borders. For low concentrations, these effects were accompanied by less prominent submembranous filaments but not by evidence of cytotoxicity, increased cell death or altered amounts of ZO-1. Tumor necrosis factor-beta induced similar alterations but interferon-y did not. Co-treatment with either cytokine increased H2O2 effects whereas IFN-beta reversed H2O2-induced effects. In control white matter samples, EC cytoplasm was clear and ZO-1 was located on cell borders. In inflammatory/demyelinating lesions, EC ZO-1 was diffuse, indicating that the alterations induced in vitro mimic those in active MS lesions. These findings suggest that in MS patients, IFN-beta treatment may counteract inflammatory mediator effects on CNS EC tight junction molecules, thereby preserving EC barrier function.
More Related Videos
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
06:19Reconstruction of the Blood-Brain Barrier In Vitro to Model and Therapeutically Target Neurological Disease
Published on: October 20, 2023
Related Concept Videos
The Blood-brain Barrier
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inhibitors of Viral Protein Synthesis
Encephalitis ll: Pathophysiology